Immune predictors of cancer progression

Immunologic Research

Volumn 53, Issue 1-3, 2012, Pages 229-234

  Toh, Benjamin ^a   Chew, Valerie ^a   Dai, Xilei ^a   Khoo, Karen ^a   Tham, Muly ^a   Wai, Lu En ^a   Hubert, Sandra ^a   Velumani, Sumathy ^a   Zhi, Liang ^a   Huang, Caleb ^a   Abastado, Jean Pierre ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Cancer; Chemokines; Epithelial mesenchymal transition; Granulocytic myeloid derived suppressor cells (G MDSC); Hepatocellular carcinoma; Immunosurveillance; Inflammation; Melanoma

Indexed keywords

CHEMOKINE;

ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INCIDENCE; CANCER RISK; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; CELL MOVEMENT; CHEMOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY; IMMUNOLOGIC SURVEILLANCE; MICE; MICE, TRANSGENIC; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84866734419     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8288-4     Document Type: Article

References (26)

1. Pazdur R, Wagman L, Camphausen K, Hoskins W. Cancer management: a multidisciplinary approach. 11th ed. Huntington: PRR; 2008.
2. Edlich RF, Winters KL, Cox MJ, Becker DG, Horowitz JH, Nichter LS, Britt LD, Edlich TJ III, Long WB. National health strategies to reduce sun exposure in Australia and the United States. J Long Term Eff Med Implant. 2004;14(3):215-24. Epub 2004/08/11.
3. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer: a global and regional generalized cost-effectiveness analysis. Vaccine. 2009;27(43): 6060-79. doi:10.1016/j. vaccine.2009.07.026. Epub 2009/08/04.
4. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010; 304(21):2373-80. doi:10.1001/jama.2010.1720. Epub 2010/12/02.
5. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587. Epub 2009/07/11.
6. Tham M, Abastado J. Escape of tumor immune surveillance and metastasis. Drug Discov Today: Dis Models. 2011;8:81-6.
7. Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prevost- Blondel A. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol. 2008;180(1):130-7.
8. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998;17(14):1885-8.
9. Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol. 1996;156(7):2473-80.
10. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208. doi:10.1146/annurev.immunol.24.021605.090733. Epub 2006/03/23.
11. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, Kato M, Prevost-Blondel A, Chow P, Yang H, Abastado JP. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010;120(6):2030-9.
12. Dragani TA, Peissel B, Zanesi N, Aloisi A, Dai Y, Kato M, Suzuki H, Nakashima I. Mapping of melanoma modifier loci in RET transgenic mice. Jpn J Cancer Res. 2000;91(11):1142-7.
13. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP. Mesenchymal transition and dissemination of cancer cells is driven by myeloidderived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162. doi:10.1371/journal.pbio.1001162 PBIOLOGY-D-11-02093. Epub 2011/10/08.
14. Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004;4:4. Epub 2004/05/20.
15. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909-15.
16. Lengagne R, Le Gal FA, Garcette M, Fiette L, Ave P, Kato M, Briand JP, Massot C, Nakashima I, Renia L, Guillet JG, Prevost- Blondel A. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8? T cells. Cancer Res. 2004;64(4):1496-501.
17. Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prevost-Blondel A, Avril MF, Nardin A, Abastado JP. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T cell infiltration and tumor control. Cancer Res. 2011;. doi:10.1158/0008-5472.CAN- 11-1466. Epub 2011/09/29.
18. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715-27. doi:10.1038/nri1936. Epub 2006/09/16.
19. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74. doi:10.1038/nri2506. Epub 2009/02/07.
20. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8): 4499-506.
21. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2): 238-44. doi:10.1016/j.coi.2010.01.021. Epub 2010/02/23.
22. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28-36. doi:10.1038/nm1699. Epub 2007/12/25.
23. Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D, Kos F, Teague J, Jiang Y, Barat NC, Jungbluth AA. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol. 2010;185(11):7107-14. doi:10.4049/jimmu nol.1002756. Epub 2010/11/03.
24. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2011;. doi:10.1136/gutjnl-2011-300509. Epub 2011/09/21.
25. Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, Garcette M, Caignard A, Avril MF, Abastado JP, Prevost- Blondel A. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol. 2011;131(9):1896-905. doi:10.1038/jid.2011.128. Epub 2011/06/10.
26. Hong M, Abastado J. How to develop better screens for anticancer therapies? OncoImmunology. 2012;1(3).